Biotechnology company Bharat Biotech said on Sunday that Covaxin, its candidate for the coronavirus vaccine, would be at least 60% effective, News18 reported. The statement was based on candidate data for the vaccine.
The company said that while aiming to achieve at least 60% efficiency, it could actually be more. The chances of the vaccine being less than 50% effective are remote, as suggested by our test results so far, he said.
The World Health Organization had said that a clear demonstration of efficacy (based on population) ideally with a score of 50% should be a minimum criterion for any candidate for coronavirus vaccines. He also said that efficacy could be assessed against illness, serious illness and / or decline.
Malini Aisola, the co-caller of the All India Drug Action Network, raised questions about the company’s claims. Bharat Biotech says the vaccine will be at least 60% effective before any results are known, she said in a tweet. Has not shared the results of Phase 1 and 2 Does not come clean from adverse events. The detailed protocols for Phase 1/2 and Phase 3 are not in the public domain.
However, NITI Aayog member VK Paul, a member of the Vaccine Centers expert group, told the news channel that data from early trials would be available after the completion of the Phase 3 trials.
The company said Tuesday it had begun trials of the third phase of the vaccine with 26,000 participants from all 22 countries in the country. She is conducting the trail in collaboration with the Indian Medical Research Council.
The vaccine has so far been evaluated in 1,000 subjects in Phase I and Phase II clinical trials, the company said. Earlier this month, senior ICMR scientist Ryan Kant had expressed hope that the Bharat Biotech vaccine might be available as early as February, months earlier than expected.
Drugmaker Pfizer on Wednesday said its vaccine showed 95% efficacy in phase 3 trials. Biotechnology company Moderna also said its vaccine candidate was found to be 94.5% effective against the virus during its three-phase trials. .
Meanwhile, India on Sunday registered 45,209 new cases of coronavirus, bringing the number of countries to 90,95,806. The number rose to 1,33,227 with 501 more deaths. The number of active cases was 4,40,962. So far, 85,21,617 people have recovered from the disease.
Race for vaccines
With so much Covid-19 vaccines in development, more results are likely to follow in the coming months. Pfizer, who has completed his trial, filed a petition Friday authorizing emergency use of the vaccine. Another vaccine candidate developed by the University of Oxford and AstraZeneca has produced strong immune responses in older adults in second-stage trials.
India has not yet signed an agreement on a coronavirus vaccine, so it is unclear when it will be available for use in the country, despite some leaders promising it will be available from January. Vaccine availability in India will be subject to approval by local regulators and the Indian government agrees to purchase them. So far, many other nations, including the United States, the United Kingdom, the European Union, Australia, and Israel, have agreed to purchase millions of doses of vaccine.
In addition, cold storage requirements also pose a challenge for developing countries like India in vaccine procurement. For example, the Pfizers vaccine should be transported and stored at freezing temperatures of minus 70 degrees Celsius from the moment they are bottled until they are ready to be injected. This is significantly lower than the standard storage requirement of 2-8 degrees Celsius. India currently does not have the system or infrastructure to be able to deliver a vaccine minus 80 degrees Celsius.
A research by the German logistics firm DHL and consulting firm McKinsey has found that insufficient cooling facilities of the last mile in the final stages of birth and lack of storage in clinics in large parts of Africa, Asia and South America would pose the greatest challenge to the widespread distribution of these vaccines.
The health ministry said on November 18 that the government is considering all possibilities for procuring these vaccines despite the challenges.